Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations
University Hospital Ulm · The University of Texas MD Anderson Cancer Center · +29 more institutions
Indexed incrossrefpubmed
Abstract
ABSTRACT: The European LeukemiaNet (ELN) genetic risk classifications were developed based on data from younger adults receiving intensive chemotherapy. Emerging analyses from patients receiving less-intensive therapies prompted a proposal for an ELN genetic risk classification specifically for this patient population.
Citation impact
182
total citations
- FWCI
- 73.72
- Percentile
- 100%
- References
- 27
Citations per year
Authors
23- HDHartmut DöhnerCorresponding
University Hospital Ulm
- CDCourtney D. DiNardo
The University of Texas MD Anderson Cancer Center
- FAFrederick Appelbaum
University of Washington, Fred Hutch Cancer Center
- CCCharles Craddock
University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital Birmingham, University of Warwick
- HDHervé Dombret
Université Paris Cité, Assistance Publique – Hôpitaux de Paris, Hôpital Saint-Louis
Topics & keywords
Topics
Keywords
- Medicine
- Intensive care medicine
- Population
- Risk assessment
- MEDLINE
- Internal medicine
- Oncology
- Environmental health
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- PPfizer
- AAstraZeneca
- GSGilead Sciences
- APAlexion Pharmaceuticals
- CCelgene
- JPJazz Pharmaceuticals
- APAstex Pharmaceuticals
- FTFoghorn Therapeutics
- APAgios Pharmaceuticals
- SPSyndax Pharmaceuticals
- DFDeutsche ForschungsgemeinschaftAwards: SFB 1074, project A02, FOR 2674
- APAstellas Pharma
- SServier
- GGenentech
- MRMedical Research Council
- NHNational Health and Medical Research Council
- DSDaiichi Sankyo Europe